250 related articles for article (PubMed ID: 20376625)
1. Possible beneficial effect of bisphosphonates in osteonecrosis of the knee.
Kraenzlin ME; Graf C; Meier C; Kraenzlin C; Friedrich NF
Knee Surg Sports Traumatol Arthrosc; 2010 Dec; 18(12):1638-44. PubMed ID: 20376625
[TBL] [Abstract][Full Text] [Related]
2. Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial.
Meier C; Kraenzlin C; Friederich NF; Wischer T; Grize L; Meier CR; Kraenzlin ME
Osteoporos Int; 2014 Jan; 25(1):359-66. PubMed ID: 24264372
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate combination therapy for non-femoral avascular necrosis.
Agarwala S; Vijayvargiya M
J Orthop Surg Res; 2019 Apr; 14(1):112. PubMed ID: 31018848
[TBL] [Abstract][Full Text] [Related]
4. Treatment of spontaneous osteonecrosis of the knee (SPONK) by a bisphosphonate.
Jureus J; Lindstrand A; Geijer M; Roberts D; Tägil M
Acta Orthop; 2012 Oct; 83(5):511-4. PubMed ID: 22998531
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.
Nguyen T; Zacharin MR
J Pediatr Endocrinol Metab; 2006 Feb; 19(2):161-7. PubMed ID: 16562590
[TBL] [Abstract][Full Text] [Related]
6. Does alendronate prevent collapse in osteonecrosis of the femoral head?
Nishii T; Sugano N; Miki H; Hashimoto J; Yoshikawa H
Clin Orthop Relat Res; 2006 Feb; 443():273-9. PubMed ID: 16462451
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate for spontaneous osteonecrosis of the knee: A protocol for systematic review and meta-analysis of randomized controlled trials.
Shen Z; Chen Z; Xie Z; Xu Y; Wang T; Li J; Yuan C; Liu J; Shi X; Ai Y; Dong W; Guo Y
Medicine (Baltimore); 2020 Dec; 99(49):e23123. PubMed ID: 33285686
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates for Paget's disease of bone in adults.
Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates for osteoporosis in primary biliary cirrhosis.
Rudic JS; Giljaca V; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2011 Dec; (12):CD009144. PubMed ID: 22161446
[TBL] [Abstract][Full Text] [Related]
11. Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Keel C; Kraenzlin ME; Kraenzlin CA; Müller B; Meier C
J Bone Miner Metab; 2010; 28(1):68-76. PubMed ID: 19633810
[TBL] [Abstract][Full Text] [Related]
12. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
13. QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
Amin NL; James RM; Phillips R
Arch Dis Child; 2016 Mar; 101(3):287-90. PubMed ID: 26768828
[No Abstract] [Full Text] [Related]
14. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.
Lai KA; Shen WJ; Yang CY; Shao CJ; Hsu JT; Lin RM
J Bone Joint Surg Am; 2005 Oct; 87(10):2155-9. PubMed ID: 16203877
[TBL] [Abstract][Full Text] [Related]
15. Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw.
Ohbayashi Y; Miyake M; Sawai F; Minami Y; Iwasaki A; Matsui Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Apr; 115(4):e31-7. PubMed ID: 23246226
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.
Müller F; Appelt KA; Meier C; Suhm N
Knee Surg Sports Traumatol Arthrosc; 2020 Feb; 28(2):408-417. PubMed ID: 31273410
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
J Oral Maxillofac Surg; 2009 Jan; 67(1):159-61. PubMed ID: 19070762
[TBL] [Abstract][Full Text] [Related]
18. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws.
Lehrer S; Montazem A; Ramanathan L; Pessin-Minsley M; Pfail J; Stock RG; Kogan R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):389-91. PubMed ID: 18554944
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate treatment in children with acute lymphoblastic leukemia and osteonecrosis - radiological and clinical findings in a national cohort.
Utriainen P; Niinimäki TT; Huurre AJ; Vepsäläinen KL; Mäkitie OM; Niinimäki RA
Acta Oncol; 2021 Sep; 60(9):1140-1145. PubMed ID: 34309491
[No Abstract] [Full Text] [Related]
20. Does Zoledronate Prevent Femoral Head Collapse from Osteonecrosis? A Prospective, Randomized, Open-Label, Multicenter Study.
Lee YK; Ha YC; Cho YJ; Suh KT; Kim SY; Won YY; Min BW; Yoon TR; Kim HJ; Koo KH
J Bone Joint Surg Am; 2015 Jul; 97(14):1142-8. PubMed ID: 26178889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
